Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Recommended treatment schedule
Prime Medicine
COVID-19
1 trial -
Reducing Antibiotics treatment duration
United Therapeutics Europe Ltd
Ventilator Associated Pneumonia
1 trial -
Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE
Hoffmann-La Roche
This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
1 trial -
Rukobia 600 mg prolonged-release tablets
ViiV Healthcare Pty Ltd
Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1
1 trial -
SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)
Takeda
Primary Immunodeficiency Diseases (PID)
1 trial -
SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion
Pari Pharma GmbH
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment
1 trial -
Sildenafil placebo, Remidia, 20 mg, tabletki powlekane
Cardiol Therapeutics
Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
1 trial -
Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)
Pari Pharma GmbH
Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)
1 trial -
Standard of Care Treatment
Kyverna Therapeutics
Myasthenia Gravis
1 trial -
Standard treatment: Control arm
United Therapeutics Europe Ltd
Cervical Carcinoma
1 trial -
The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.
Lacuna Pharma Pty Ltd
treatment-resistant schizophrenia (TRS)
1 trial -
The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα
Lacuna Pharma Pty Ltd
Second line treatment for colonoscopy preparation
1 trial -
Tildrakizumab matching placebo, Enbrel 25 mg powder for solution for injection, Tildrakizumab
Lacuna Pharma Pty Ltd
Treatment of pediatric subjects with moderate to severe chronic plaque psoriasis
1 trial -
Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)
Rare Thyroid Therapeutics International AB
Monocarboxylate Transporter 8 (MCT8) deficiency
1 trial -
Treatment as Usual (TAU)
BRIGHT MINDS BIOSCIENCES INC.
Drug Addiction
1 trial -
Treatment group
United Therapeutics Europe Ltd
Post Operative Surgical Site Infection
1 trial -
Treatment of TongBi Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Knee Osteoarthritis
1 trial -
Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.
The First People's Hospital of Lianyungang
Post-stroke Epilepsy
1 trial -
Trulicity 0.75 mg solution for injection in pre-filled pen
The George Institute
Preventive treatment of post-kidney transplant diabetes
1 trial -
Vortioxetine
Takeda
Treatment Outcome
1 trial -
Zanubrutinib, BGB-11417, BGB-11417, BGB-11417, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, BGB-11417, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets
BEONE MEDICINES AUS PTY LTD
treatment-naive Chronic Lymphocytic Leukemia
1 trial -
Zometa 4 mg/100 ml solution for infusion, XGEVA 120 mg solution for injection in pre-filled syringe
CERO THERAPEUTICS HOLDINGS, INC.
Patients, men or women over 18 old, with inoperable vertebral bone metastases who must beneficit treatment with stereotactic radiotherapy
1 trial -
alprazolam, Placebo matching Staccato® alprazolam and without active substance
Lacuna Pharma Pty Ltd
Treatment of stereotypical prolonged seizure
1 trial -
514G3 (2 mg/kg) plus standard IV antibiotic treatment
XBiotech Germany GmbH
Staphylococcus Aureus Bacteremia
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources